Logo image of ITRM

ITERUM THERAPEUTICS PLC (ITRM) Stock Fundamental Analysis

NASDAQ:ITRM - Nasdaq - IE000TTOOBX0 - Common Stock - Currency: USD

1  +0.01 (+0.92%)

After market: 1.005 +0 (+0.5%)

Fundamental Rating

1

ITRM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of ITRM have multiple concerns. ITRM is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ITRM had negative earnings in the past year.
ITRM had a negative operating cash flow in the past year.
ITRM had negative earnings in each of the past 5 years.
In the past 5 years ITRM always reported negative operating cash flow.
ITRM Yearly Net Income VS EBIT VS OCF VS FCFITRM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

ITRM's Return On Assets of -68.44% is on the low side compared to the rest of the industry. ITRM is outperformed by 67.18% of its industry peers.
Industry RankSector Rank
ROA -68.44%
ROE N/A
ROIC N/A
ROA(3y)-89.08%
ROA(5y)-105.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ITRM Yearly ROA, ROE, ROICITRM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ITRM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ITRM Yearly Profit, Operating, Gross MarginsITRM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K -250K

More info and screens

3

2. Health

2.1 Basic Checks

ITRM has more shares outstanding than it did 1 year ago.
ITRM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ITRM is higher compared to a year ago.
ITRM Yearly Shares OutstandingITRM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ITRM Yearly Total Debt VS Total AssetsITRM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -21.44, we must say that ITRM is in the distress zone and has some risk of bankruptcy.
ITRM's Altman-Z score of -21.44 is on the low side compared to the rest of the industry. ITRM is outperformed by 81.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.44
ROIC/WACCN/A
WACCN/A
ITRM Yearly LT Debt VS Equity VS FCFITRM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

ITRM has a Current Ratio of 3.72. This indicates that ITRM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.72, ITRM is in the better half of the industry, outperforming 61.54% of the companies in the same industry.
A Quick Ratio of 3.58 indicates that ITRM has no problem at all paying its short term obligations.
ITRM has a Quick ratio of 3.58. This is in the better half of the industry: ITRM outperforms 62.05% of its industry peers.
Industry RankSector Rank
Current Ratio 3.72
Quick Ratio 3.58
ITRM Yearly Current Assets VS Current LiabilitesITRM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.40% over the past year.
EPS 1Y (TTM)63.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ITRM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.81% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.56%
EPS Next 2Y18.28%
EPS Next 3Y12.89%
EPS Next 5Y23.81%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ITRM Yearly Revenue VS EstimatesITRM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ITRM Yearly EPS VS EstimatesITRM Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ITRM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ITRM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ITRM Price Earnings VS Forward Price EarningsITRM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ITRM Per share dataITRM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

ITRM's earnings are expected to grow with 12.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.28%
EPS Next 3Y12.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ITRM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ITERUM THERAPEUTICS PLC

NASDAQ:ITRM (6/16/2025, 8:00:02 PM)

After market: 1.005 +0 (+0.5%)

1

+0.01 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners2.79%
Inst Owner Change-9.23%
Ins Owners1.03%
Ins Owner Change0%
Market Cap40.00M
Analysts82.5
Price Target7.14 (614%)
Short Float %3.25%
Short Ratio2.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.23%
Min EPS beat(2)-4.88%
Max EPS beat(2)5.34%
EPS beat(4)2
Avg EPS beat(4)-2.99%
Min EPS beat(4)-47.06%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)14.67%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40%
PT rev (3m)-6.67%
EPS NQ rev (1m)11.11%
EPS NQ rev (3m)36.84%
EPS NY rev (1m)0%
EPS NY rev (3m)17.81%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)48.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0
BVpS-0.06
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.44%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-89.08%
ROA(5y)-105.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.72
Quick Ratio 3.58
Altman-Z -21.44
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1.59%
Cap/Depr(5y)2.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.57%
EPS Next Y52.56%
EPS Next 2Y18.28%
EPS Next 3Y12.89%
EPS Next 5Y23.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y63.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3Y55.73%
EBIT Next 5YN/A
FCF growth 1Y31.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.72%
OCF growth 3YN/A
OCF growth 5YN/A